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Available online 19 February 2011.Inhibitors of proteasomes have been shown to affect endocytosis ofmultiplemembrane receptors, in
particular at the step of cargo sorting for lysosomal degradation. Here we demonstrate that the
inhibition of proteasomes causes specific redistribution of an endosomal adaptor APPL1, which
undergoes initial solubilization from APPL endosomes followed by clustering in the perinuclear
region. MG132 treatment decreases APPL1 labeling of endosomeswhile the staining of the canonical
early endosomes with EEA1 remains unaffected. Upon prolonged treatment with proteasome
inhibitors, endogenous APPL1 localizes to the site of aggresome formation, with perinuclear APPL1
clusters encapsulatedwithin a vimentin cage and co-localizingwith aggregates positive for ubiquitin.
The clustering of APPL1 is concomitant with increased ubiquitination and decreased solubility of this
protein. We determined that the ubiquitin ligase Nedd4 enhances polyubiquitination of APPL1, and
the ubiquitinmolecules attached to APPL1 are linked through lysine-63. Taken together, these results
add APPL1 to only a handful of endogenous cellular proteins known to be recruited to aggresomes
induced by proteasomal stress. Moreover, our studies suggest that the proteasome inhibitors that are
already in clinical use affect the localization, ubiquitination and solubility of APPL1.
© 2011 Elsevier Inc.
 






Receptor-mediated endocytosis is a process by which cells internal-
ize extracellular ligands. It is initiated by the inward budding of
plasma membrane vesicles containing ligands bound to specific
transmembrane receptors. Among other routes, receptors can be
internalized via clathrin-coated pits that pinch off, lose their clathrin
coat and fuse with an endosomal compartment where the cargo is
sorted towards recycling or degradation in lysosomes. Several
endosomal populations can be distinguished based on the presence
of specific markers as well as functional and morphological
characteristics. Early endosomes that contain the small GTPase6.
. Miaczynska).
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 C BY license.Rab5 and EEA1 (early endosome antigen1) are the first cargo sorting
platform [1]. A subpopulation of early endosomes, initially charac-
terized by the presence of APPL1 protein as a uniquemarker [2], are
called APPL1-positive vesicles or APPL endosomes [3]. From early
endosomes various types of cargo are transported to recycling
endosomes, late endosomes and lysosomes, or towards the Golgi
apparatus.
Ubiquitination acts as a signal for the internalization and sorting
of plasma membrane proteins along the endocytic route (reviewed
in [4]). In contrast to the well-established function of polyubiqui-
tination in proteasome-dependent protein degradation, the ubiqui-
tination involved in endocytosis does not lead to protein destructionn and leucine zipper motif; EEA1, early endosome antigen 1; GFP, green
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growth factor (EGF) receptor there are several stages sensitive to the
inhibitors of proteasome, namely the sorting from early to late
endosomes and the translocation of activated EGF receptor from the
outer limiting membrane to the inner membranes of multivesicular
bodies (MVBs) [5,6]. Ubiquitin-dependent sorting is specific to
endocytosed cargo, as proteasomal inhibitors block ligand-induced
internalization of glutamate receptors, butnot of transferrin receptor
[7]. In general, inhibition of proteasomes blocks the sorting of
membrane receptors towards degradation without interfering with
the transport of soluble proteins or recycling cargo [8]. The
applicationof proteasome inhibitorsdecreases the rates of lysosomal
degradation of multiple transmembrane receptors, including those
for EGF [9], growth hormone and nerve growth factor [8], platelet-
derived growth factor [10], hepatocyte growth factor [11], interleukin-
2 [12] and low-density lipoprotein receptor-related protein [7].
In contrast to the general knowledge about the involvement
of ubiquitin–proteasome system in endocytosis, specific effects of
proteasome inhibitors on early endosomes are not known. In
particular, we were interested in the fate of the subpopulation of
early endosomes marked by the presence of APPL1, which act as a
sorting and signaling platform. APPL endosomes are positive for
Rab5 but not EEA1 (which is a marker for the canonical early
endosomes), and are preferentially localized underneath the plasma
membrane [2]. APPL1 is primarily recruited to endocyticmembranes
through binding to the small GTPase Rab5. The endocytic compart-
ments are highly dynamic, and changes in the composition of
phosphoinositides on early endocytic membranes cause a selective
recruitment of either APPL1 or EEA1 to Rab5-positive endosomal
vesicles [3]. APPL endosomes participate in endocytic trafficking of
EGF receptor [2] and transferrin receptor (our unpublished results).
In addition, they function as platforms for the assembly of signaling
complexes that control distinct signal transduction pathways, e.g.
the Akt and MAPK pathways [3,13]. APPL1, a unique marker of APPL
endosomes, interacts with Akt and phosphatidylinositol 3-kinase, as
well as with several membrane receptors (including adiponectin
receptor 1 and2, netrin-1 receptorDCC, follicle stimulatinghormone
receptor, and nerve growth factor receptor TrkA), contributing
to signal transduction downstream of these receptors (reviewed in
[14]). The cellular functions of APPL1 are not limited to endocytosis,
and include also regulation of gene transcription, metabolism, cell
proliferation and cell survival [14]. Recently, we reported that APPL1
can activate β-catenin-dependent transcription [15] and interact
with the NuRD chromatin remodeling and histone deacetylase
complex [2,16].
While proteasomal inhibition affects endocytic trafficking already
upon short application (1 h or less), prolonged (12–24 h) treatment
causes massive changes in the turnover of cellular proteins. Protea-
somedeficiency stimulates a cellular stress responseby inducing time-
and dose-dependent inhibition of cell growth, arrest of the cell cycle,
apoptosis, aswell as the lossofmitochondrialmembranepotential and
increase in the intracellular ROS levels [17]. Compromised proteaso-
mal function leads to the accumulation of misfolded proteins which
become sequestered into large, insoluble, non-membranous protein
deposits called aggresomes. These structures were first described by
Wojcik et al. inHeLa cells treatedwith apeptide aldehydeproteasomal
inhibitor PSI [18], and named aggresomes by Johnston et al. [19].
Aggresomes appear either as a single sphere with a diameter of 1–
3 μm positioned at an indentation of the nucleus, or as an extended
ribbon around the nuclear envelope [20]. Aggresomes assemble in theperinuclear region near the microtubule organizing center, and their
formation involves trafficking of aggregated proteins along micro-
tubules and reorganization of intermediate filaments [19–21]. Aggre-
somes recruit chaperones, ubiquitination enzymes and components of
the ubiquitin–proteasome machinery, to help in the disposal of
aggregated proteins. The process of aggresome clearance is largely
dependent on the autophagy–lysosome system. The cellular site of
aggresome formation is enriched in double-membrane vesicles
representing autophagosomes, and blockage of autophagy impairs
the clearance of aggresomes [22]. Lysosomes gather close to the
aggresome and eventually digest the proteins forming the inclusions.
Here, we aimed to characterize an effect of proteasomal
inhibition on APPL endosomes. We analyzed the localization and
morphometric features of APPL1-positive endosomes upon a
range of incubation times with proteasome inhibitors. Strikingly,
we observed initial solubilization of APPL1 from endosomal
membranes followed by its relocalization to aggresomes which
correlated with increased ubiquitination and insolubility of
APPL1.Materials and methods
Antibodies and chemicals
Anti-APPL1 polyclonal antibodies against C-terminal peptides were
raised in rabbits (Eurogentech) and previously described [2,15]. The
following mouse monoclonal antibodies were used for immunofluo-
rescence: anti-EEA1 and GM130 (BD Transduction Laboratories),
CD63 (Developmental Studies Hybridoma Bank), Rab5 (D-11, Santa
Cruz Biotechnology), ubiquitin (FK1, Biomol), vimentin and GFP
(Sigma-Aldrich). Alexa Fluor 405-, 488- and 555-conjugated anti-
mouse and anti-rabbit antibodies, as well as EGF and transferrin
labeled with Alexa Fluor 488 were from Invitrogen. Additional
antibodies were used in Western blotting: mouse antibodies against
HAandubiquitin P4D1 (Santa CruzBiotechnology),α-tubulin,β-actin
and FLAG (M2) (Sigma-Aldrich), HDAC2 (Upstate), and goat antibody
against GFP (MPI, Dresden). Secondary horseradish peroxidase-
conjugated antibodies were from Jackson ImmunoResearch. Mito-
Tracker Orange probe (Invitrogen) was used according to provider's
instructions. Cycloheximide, 4′,6-diamidino-2-phenylindole (DAPI),
N-ethylmaleimide (NEM) and nocodazole were purchased from
Sigma-Aldrich. Proteasome inhibitors MG132, ALLN and clasto-
lactacystin β-lactone were from Sigma-Aldrich, and bortezomib
from LC Laboratories. The inhibitors were diluted in dimethyl
sulfoxide (DMSO) and an equivalent volume of DMSO was used in
all experiments as a solvent control.
Plasmids and siRNA reagents
The constructs of untagged, Myc-tagged and GFP-tagged APPL1
were previously described [2]. The expression constructs of FLAG-
and HA-tagged ubiquitin wild type, HA-tagged ubiquitin mutant
K63R, HA-tagged c-Cbl and untagged Nedd4 were a gift from Ivan
Dikic. The HA-ubiquitin K63-only expression construct was
provided by Ted M. Dawson (Addgene plasmid 17606) [23]. The
mouse HA-Nedd4-1 expression construct was provided by Allan
M. Weissman (Addgene plasmid 11426) [24]. The mouse GFP-
Eps15 construct was previously described [25].
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human APPL1 from HP GenomeWide siRNA collection (Qiagen):
(APPL1-a) Cat. No. SI02652125, (APPL1-b) Cat. No. SI03128979.
Alongside, two siRNA negative controls were used (Qiagen):
(control-a) Cat. No. 1027280 and (control-b) Cat. No. 1022076.
Cell culture and transfections
Human cell lines HEK293 (embryonic kidney) and HeLa (cervix
carcinoma)were cultured as previously described [15]. HEK293 cells
were transiently transfected using the calcium phosphate method
[26]. For microscopical analysis, HeLa cells were transfected with
0.5 μg of plasmid DNA in 24-well plates using FuGene reagent
(Roche), treated as indicated and fixed 48 h post-transfection.
Duplexes of siRNA (10 nM) were delivered to HeLa cells using
HiPerFect reagent (Qiagen) according tomanufacturer's instructions.
Immunofluorescence
HeLa cells were processed for immunofluorescence staining as
previously described [16]. Images were acquired on a Zeiss LSM510
laser scanningconfocalmicroscopewith a 63×/1.4 Plan-Apochromat
oil immersion objective and argon and HeNe lasers. Z-stacks were
built and converted to maximal intensity projections (MIPs) using
ZEN 2009 Light Edition. The presented microscopy images were
assembled using Adobe Photoshop 7.0.
Quantification of microscopical images
For morphometric image analysis we used the custom-designed
image analysis software MotionTracking/Kalaimoscope (www.
kalaimoscope.com) [27,28]. In brief, endosomes were automati-
cally identified as fluorescent objects based on the user-defined
parameters i.e. pixel fluorescence intensity, minimum area and
resolution limit, using an algorithm implemented in MotionTracking.
The software created a synthetic image with identified vesicles and
subtracted extracellular and intracellular background, and performed
statistical analysis ofmodelledendosomes. Statistical parameterswere
calculated per overall area occupied by the cells. Quantification of the
endocytic phenotypes included the following parameters: the number
of vesicles, the mean apparent area of the cross section of vesicles
expressed in μm2 (corresponding to the average vesicle size), and the
total fluorescence of a fluorophore detected in all vesicles, defined as
the total integral vesicle intensity. These parameters were calculated
separately for red (APPL1) and green (EEA1) channels based onmore
than a hundred of imaged cells per condition.
For quantification of APPL1 clusters, we counted the HeLa cells
containing perinuclear clusters positive for APPL1. For quantifica-
tion of ubiquitin aggregates, we counted the HeLa cells containing
four arbitrary chosen and easily distinguishable types of ubiquitin
distribution. The calculations were based on the indicated number
of scored cells and expressed as a percentage of all counted cells.
Images from confocal microscope were taken with a maximally
opened pinhole (8.89 Airy Units, corresponding to 6.9-μm-thick
section) in order to view the entire cell volume.
Lysis, Western blotting and immunoprecipitation
Cells were lysed in RIPA buffer containing 1% Triton X-100, 0.5%
deoxycholate, 0.1% SDS, 50 mM Tris–Cl (pH 7.4), 150 mM NaCl,0.5 mMEDTAandprotease inhibitor cocktail. Soluble lysate samplesof
10–20 μg total protein were subjected to SDS-PAGE. Protein concen-
trationwasmeasuredwith Bradford assay (Roth).Where appropriate,
insoluble fractions were prepared from cellular pellets formed upon
extraction for 20min on ice with RIPA buffer, followed by centrifu-
gation at 20,000g for 15 min. The pellets were washed and boiled in
SDS-PAGE sample buffer. Total cellular lysates were prepared by
adding hot SDS-PAGE sample buffer to the dish with adherent cells,
scrapingandboilingprior to loadingon thegel. Resolvedproteinswere
transferred to nitrocellulose membrane (Whatman), probed with
specific antibodies, and detected with enhanced chemiluminescence.
Proteins of interest were immunoprecipitated from soluble
lysates containing 100–200 μg of protein by 2-h incubation with
an appropriate antibody at 4 °C with constant rotation, recovery of
immunocomplexes on protein A sepharose beads (Roche), washing
in IP buffer (1% Triton X-100, 50 mMHepes (pH 7.4), 150 mMNaCl,
1 mM EDTA, 1 mM EGTA, 10% glycerol), and elution with SDS-PAGE
sample buffer. Where indicated, non-immune rabbit immunoglo-
bulins were used in control immunoprecipitations.
Statistical analysis
The statistical significance was assessed by using the Mann–
Whitney U test. The level of significance was set at p<0.05.
Analyses were performed using GraphPad Prism software.Results
Inhibition of proteasomes causes redistribution of APPL1
In order to investigate the effect of proteasome inhibitors on APPL
endosomes, we looked at the distribution of endogenous APPL1 in
HeLa cells treated with MG132, ALLN, or bortezomib. Both MG132
and ALLN are cell-permeable peptide aldehydes commonly used as
reversible inhibitors of the chymotrypsin-like proteolytic activity of
the proteasome. Bortezomib (Velcade), a dipeptide boronic acid
analogue, has increased affinity for the catalytic subunits of
the proteasome and reduced multidrug resistance sensitivity. It
represents a prototype of highly effective anti-cancer agents, used
for treatment of two B-cell malignancies: multiple myeloma and
mantle cell lymphoma [29,30]. We used MG132 at two concentra-
tions (5 or 10 μM), ALLN at 50 μM, and bortezomib at 1 μM, for times
ranging from 1 h till 20 h. Fig. 1 shows representative images of
maximal intensity projection (MIP) covering the entire cell volume.
The individual confocal scans taken from the bottom and themiddle
of the cells are shown in Fig. S1. In DMSO-treated control cells,
APPL1-positive endosomes are dispersed in the cytoplasm and in
particular concentrated underneath the plasma membrane. One-
hour treatment with the inhibitors did not cause any observable
changes compared to the control cells (data not shown). Both 6- and
20-h treatmentswith the inhibitors caused amarked decrease in the
number of APPL endosomes close to the ventral cell membrane
facing the glass (Fig. S1, middle panels). Interestingly, we observed
clusters of APPL1-positive structures formed in the perinuclear
region upon 20-h treatment with MG132, ALLN and bortezomib
(Fig. 1 and Fig. S1, right panels).
In order to check whether the changes in APPL1 distribution
upon prolonged proteasomal inhibition are specific, we looked
at the localization of other proteins residing on early or late
Fig. 1 – Changed distribution of APPL1 upon proteasomal
inhibition. HeLa cells seeded on coverslips were treated for 20
h with 5 μM MG132, 50 μM ALLN, 1 μM bortezomib, or a
corresponding amount of DMSO (the solvent control). The cells
were fixed, permeabilized, and stained for APPL1 followed by
Alexa555-conjugated anti-rabbit antibodies. The panels show
maximum intensity projections (MIP) of z-stacks containing
7–9 confocal images taken every 0.5 μm throughout the entire
volume of the cells. The examples of single scans used for the
construction of MIPs are shown in Fig. S1. Bar, 20 μm.
1096 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 7 ( 2 0 1 1 ) 1 0 9 3 – 1 1 0 7endosomes as well as at the distribution of other cellular
organelles (Fig. S2). We found that the distribution of early
endosomal marker Rab5, present on APPL endosomes, followed
the pattern of changes displayed by APPL1: both proteins were
solubilized from endosomal membranes upon 6-h MG132 treat-
ment, and co-localized in perinuclear clusters upon 20-h treat-
ment. In contrast, EEA1, selectively residing on the canonical early
endosomes, showed no obvious redistribution (Fig. S2). CD63, a
marker of late endosomal and lysosomal membranes, changed the
localization in cells treated for 20 h with MG132, but it did not co-
localize with APPL1 clusters (Fig. S2). The same was true for
mitochondria (stained with MitoTracker Orange probe) and the
Golgi apparatus (stained with anti-GM130 antibody) (Fig. S2). The
observed redistribution of cellular organelles was in agreement
with the literature data [31–33]. We conclude that proteasomal
stress selectively affects endosomes containing APPL1 and Rab5.
In order to quantify the extent of observed changes in APPL1
localization, morphometric features of APPL1- and EEA1-containing
endosomes were compared using the image analysis software
MotionTracking [27,28]. Upon analysis of the double-immunolabelled
images, we quantified the following parameters for APPL1 and EEA1
endosomes: the number of vesicles, the average vesicle size (mean
apparent area), and the total integral vesicle intensity (sum of
fluorescence of all vesicles) (Fig. 2A–C and Suppl. Table 1). Fig. S3
shows representative images used for the measurements. Weobserved that the number of APPL endosomes decreased upon
MG132 treatment (to 42% and 51% of control value after 6 and 20
h of MG132 treatment, respectively) (Fig. 2A). Proteasomal inhibition
caused an initial decrease of mean area of APPL vesicles (to 78% of
control after 6 h), which returned to the control levels after 20
h(Fig. 2B). In addition, theoverall numberofAPPL1molecules residing
on endosomes dropped upon MG132 treatment (measured as total
integral intensity of all vesicles, Fig. 2C) to 31%and41%of control value
after 6 and 20 h, respectively.
At the same time, the EEA1 endosomes displayed much less
changes. The number of EEA1 endosomes was not affected by
MG132 treatment (Fig. 2A). The area of EEA1 endosomes was
consistently decreased by MG132 treatment at 6 and 20 h (to 75%
of control; Fig. 2B). Correspondingly, the integral vesicle intensity
for EEA1 was reduced to 72% and 70% of control, for 6- and 20-
h MG132 treatment, respectively (Fig. 2C).
Based on this data,we could conclude the following: (a) Inhibition
of proteasomes decreased the number of detectable APPL endosomes
by half, while it did not affect the number of observed EEA1 vesicles;
(b)Mean size ofAPPLvesicles initially decreased andthen returned to
the control levels upon MG132 treatment, with a heterogeneous
vesicle population after 20h (bigger vesicles in theperinuclear cluster
and smaller ones scattered in the cytoplasm); (c) MG132 treatment
solubilized APPL1 from vesicles, as the massive decrease in the
amount of APPL1 bound to vesicles could not be explained by the
observed changes in the vesicle size; (d) MG132 treatment reduced
the size of EEA1 vesicles and, proportionally, the amount of vesicle-
bound EEA1. Clearly, MG132 affects both early endosomal compart-
ments (as expected due to multiple morphological changes seen in
other membraneous cellular structures). However, the extent and
timing ofMG132 effects seem to be substantially different in the case
of APPL1 and EEA1 endosomes. In the case of EEA1,MG132 treatment
primarily affected the vesicle size. In the case of APPL1, changes were
much more pronounced and involved the decreased amounts of
vesicle-bound APPL1 molecules as well as the decreased number of
detectable APPL1-positive vesicles.
Although the morphometric image analysis provided us with
quantitative data, due to averaging of analyzed parameters within
endosomal populations it was not optimal for characterizing
distinct patterns of APPL1 redistribution upon the two time
periods of MG132 treatment. To complement the initial analysis,
we counted the number of HeLa cells containing perinuclear
clusters of APPL1 upon treatment with DMSO or MG132 for 4 or
20 h. Representative images are shown in Fig. 2D.While clusters of
APPL1 were a rare event in control cells or upon 4-h MG132
treatment, upon 20-h MG132 application the number of cells
containing the perinuclear clusters of APPL1 reached almost 50% of
all counted cells (Fig. 2E).
At this point it was important to determine whether perinuclear
clustering of APPL1 represents its recruitment to endosomes
relocalized in the cell center or a formation of proteinaceous
aggregates without a surrounding membrane. We checked this by
employing continuous uptake of fluorescently labeled cargo during
the incubation with MG132 for 18 h. We used transferrin that is
constitutively recycled and EGF that undergoes degradation in
lysosomes, both labeled with Alexa Fluor 488. In addition, the cells
were stained for APPL1 and for vimentin in order to visualize
aggresomes (see Fig. 3A for more explanations). As shown in Fig. 2F,
neither transferrin nor EGF accumulated at the sites of perinuclear
APPL1 clusters, suggesting that these are not functional endosomes
Fig. 2 – MG132 influences the properties of an endosomal subpopulation harboring APPL1. (A–C) Quantification of the distribution
and morphometric properties of APPL1 and EEA1 endosomes. A detailed description is given in Material and methods section. Ten
MIPs were analyzed for every condition; each MIP was assembled from images taken at three confocal planes (bottom, middle, and
top of the cells). The results represent averaged values of each parameter with standard deviation, and are expressed as a percentage
of control values obtained from DMSO-treated cells. (A) The number of vesicles containing APPL1 or EEA1. (B) Mean area of vesicles
positive for APPL1 or EEA1. (C) Total integral fluorescence intensity of vesicles containing APPL1 or EEA1. (D) Clustering of APPL1 in
HeLa cells treatedwith proteasome inhibitor. Cells were treatedwithMG132 for 4 or 20 h, or control DMSO for 20 h. The panels show
representative images used for analysis in E. Bar, 20 μm. (E) Quantification of the perinuclear clusters of APPL1. Seven random
images were taken for each condition and the cells containing clustered APPL1 were counted and expressed as a percentage of all
scored cells (n indicates the number of scored cells). The graph shows averaged results with standard deviation of an experiment
done in duplicate, representative of three independent experiments. (F) HeLa cells seeded on coverslips were treated with DMSO or
5 μM MG132 in the presence of fluorescently labeled EGF-Alexa 488 (1 μg/ml) or transferrin-Alexa 488 (2.5 μg/ml). After 18 h of
continuous uptake the cells were fixed and co-stained for APPL1 and vimentin. Bar, 10 μm. A–C and E: *, p<0.05; ***, p<0.001; ns,
not significant compared with DMSO control (Mann–Whitney test).
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Fig. 3 – The perinuclear clusters of APPL1 co-localize with the sites of aggresome formation. (A) HeLa cells seeded on coverslips were
treatedwith control DMSO for 20 h or 10 μMMG132 for 6 or 20 h, fixed and co-stained for endogenous vimentin and APPL1 together
with the nuclear staining (blue) by DAPI. Asterisks indicate a cell without an aggresome after 20-h treatment with MG132. (B) HeLa
cells were treated as in A, and stained for endogenous ubiquitin and APPL1 together with the nuclear staining (blue) by DAPI.
(C) HeLa cells were treated with 5 μM nocodazole (NOC) for 20 h in parallel to the treatment as in A. Cells were stained as in B.
(D) HeLa cells were transiently transfectedwith GFP-Eps15, after 24 h treated as in A, and stained for an endogenous APPL1. All scale
bars A–D, 20 μm. Insets in A, B and D show magnification of APPL1 clusters from cells treated with MG132 for 20 h.
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18 h some peripheral APPL1-positive endosomes contained trans-
ferrin, while there was no co-localization of APPL1 and EGF. As
previously reported [6], MG132 markedly decreased degradation of
EGF, which accumulated in the cells treated with MG132 to a larger
extent than in control-treated cells (data not shown).
Taken together, the above-presented data allowed concluding that
upon a prolonged proteasomal inhibition APPL1 is solubilized from
endosomes and relocalizes to the perinuclear region where it forms
clusters, which are most likely proteinaceous aggregates. Theseclusters are not functional cargo-bearing vesicles and do not co-
localize with early or late endosomes, mitochondria or the Golgi
apparatus.
Co-localization of clustered APPL1 with aggresomes upon
proteasomal inhibition
As the observed perinuclear clusters of APPL1 did not represent
functional endosomes, we wished to further characterize these
aggregates. We performed a series of co-stainings of APPL1 with
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check whether the perinuclear clusters of APPL1 co-localize with
an aggresome.
One of the most typical components of aggresomes is an
intermediate filament protein vimentin that during aggresome
formation is displaced from its normal fibrillar cellular distribution
and forms a cage surrounding the core of aggregatedproteins [19–21].
Fig. 3A shows that APPL1 clusters are confined within the collapsed
vimentin cage in cells treated for 20 h with MG132. Markedly, under
this treatment every cell containing an aggresome surrounded by
vimentin also contains clustered APPL1. The one cell marked with an
asterisk in Fig. 3A has neither collapsed vimentin nor clustered APPL1.
Similarly, we saw co-localization of APPL1 and vimentin in cells
treated for 20 h with other proteasomal inhibitors, bortezomib and
clasto-lactacystinβ-lactone (Fig. S4). Interestingly, alreadyupon6hof
MG132 treatment we could observe cells containing collapsed
vimentin cages, but no APPL1 clusters (Fig. 3A).
Another component of aggresomes formed in response to a
failure of proteasome machinery are ubiquitinated proteins
[20,21]. We checked whether clusters of APPL1 form at the sites
of ubiquitin aggregation by co-staining of APPL1 and ubiquitin.
Indeed, all clusters of APPL1 were localized at a close proximity to
the perinuclear ubiquitin aggregates (Fig. 3B).
The third feature of aggresomes is their dependence on transport
along microtubules [19]. We co-treated cells with MG132 and
nocodazole, a microtubule-disrupting agent, which prevents the
assembly of aggregated proteins into a large perinuclear aggresome.
Upon treatmentwithMG132 for 20 h in the presence of nocodazole,
we could neither see the formation of ubiquitin aggregates nor
clustering of APPL1 (Fig. 3C). However, nocodazole did not affect the
localization of APPL1 in DMSO-treated cells (Fig. 3C).
It has been previously reported that several endocytic proteins
are recruited to aggresomes via their interaction with a protein
called ubiquilin that bears ubiquitin-like domain (UBL). These
are proteins possessing ubiquitin-interacting motifs (UIMs):
Eps15, Hrs and STAM2 [34]. In particular, Eps15 has been shown
to participate in the formation of aggresomes [35]. We expressed
GFP-Eps15 in HeLa cells and checked its localization in parallel
to an endogenous APPL1 upon treatment with DMSO orMG132 for
6 or 20 h (Fig. 3D). There was no co-localization of Eps15 and
APPL1 in control cells or cells treated with MG132 for 6 h.
Interestingly, upon 20-h MG132 treatment we observed not only
an aggregation of both proteins in the same region of the cells, but
also a recruitment of APPL1 to the GFP-positive aggregates in cells
expressing high levels of GFP-Eps15 (Fig. 3D). In agreement with
these observations, we could also detect Eps15 co-precipitating
with APPL1 (data not shown).
On the basis of the abovemicroscopical data, we conclude that the
perinuclear clusters of APPL1 formed upon proteasomal inhibition co-
localize with the commonly accepted aggresome markers.
Role of APPL1 in the formation and clearance of aggresomes
Since other endocytic proteins (i.e. Eps15) have been shown to
affect aggresome formation [35], we checked the influence of
APPL1 on proteasome-dependent aggregation. We overexpressed
GFP-APPL1 in HeLa cells and treated them with control DMSO or
MG132 for 6 or 20 h. Similarly to an endogenous protein, GFP-
APPL1 was localized in punctate endosomal structures under
control conditions, as previously reported [2] and was solubilizedfrom endosomes upon 6 h of MG132 treatment. Upon 20 h of
MG132, GFP-APPL1 was concentrated inmultiple large perinuclear
structures which were encapsulated by ubiquitin (Fig. 4A). To test
whether APPL1 overexpression influences formation of aggre-
somes, we compared the localization of ubiquitin-rich aggregates
in the transfected versus untransfected cells upon treatment with
MG132 for 6 and 20 h. Ubiquitin accumulated in perinuclear areas
already at 6 h of MG132 treatment, and after 20 h virtually all cells
contained aggregates of ubiquitinated proteins. However, the
extent of their formation in cells overexpressing GFP-APPL1 did
not differ from the neighboring untransfected cells, indicating that
an increased level of APPL1 does not modulate or enhance the
proteasome-dependent aggregation of ubiquitinated proteins
(Fig. 4A). Similarly, knockdown of APPL1 by siRNA had no
significant effect on the formation of MG132-indduced ubiquitin-
rich aggregates (Fig. 4B). Since in HeLa cells we achieved only
partial silencing of APPL1, it remains formally possible that the
complete knockout would affect aggregation of ubiquitinated
proteins upon proteasomal impairment. However, it is rather
likely that clustering of APPL1 is an event rather successive to than
causative of aggresome formation.
The aggregates formed upon treatment with MG132 are
reversible, and typically cells return to their normal morphology
within 24–72 h after the removal of the inhibitor. To assess the
effect of APPL1 on the clearance of aggresomes, after 18-
h incubation with MG132 we washed the cells and allowed them
to grow for the next 24 or 48 h in a normal medium. Upon 24 h of
recovery time, ubiquitin was evenly distributed throughout the
cytoplasm, with small cytoplasmic aggregates in 64% of the cells
(Fig. 4C). The aggregates were not visible in 12% of control cells,
while the cells containing the bigger clusters were classified as
“moderate” (20%) or “large” (3%) based on their size (Fig. 4C).
After 48-h recovery time, all cells had none or only small ubiquitin
aggregates. We reduced the level of APPL1 protein with the help of
two independent siRNA duplexes, and counted the cells containing
various patterns of ubiquitin distribution after 24-h recovery time.
As shown in Fig. 4C, silencing of APPL1 had no substantial effects
on the clearance of ubiquitin aggregates. However, compared to
control cells, in the cells treated with siRNA targeting APPL1, we
observed a 5% increase in the number of cells without clusters,
which could argue that, if at all, APPL1 might only have a slight
modulatory impact on the dynamics of aggresome clearance.
Ubiquitination of APPL1
We wanted to investigate whether relocalization of APPL1 to
ubiquitin-rich aggresomes is related to any changes in its own
ubiquitination status. To check if APPL1 is targeted by ubiquitin, we
overexpressed APPL1 together with HA-ubiquitin in HEK293 cells. In
such overexpression systemwe detected additional slower-migrating
bands recognized by anti-APPL1 antibodies in APPL1 immunopreci-
pitates (Fig. 5A). One strong and one weak additional bands were
visible, eachwith an apparent size difference of approximately 10 kDa
(marked with arrowheads, Fig. 5A). The HA antibody recognizing the
tagged ubiquitin detected a high molecular weight smear in APPL1
immunoprecipitates. The additional bands were not present in APPL1
immunoprecipitates from cells lacking the overexpression of ubiqui-
tin. On the other hand, such additional bands of APPL1 were visible in
the lysates upon long exposure (Fig. 5A). Thus, APPL1 is subjected to
polyubiquitination in ubiquitin-transfected HEK293 cells.
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from protein overexpression, we checked the ubiquitination of
endogenous APPL1 in HeLa cells. We failed to detect ubiquiti-
nated APPL1 under control conditions, but we could see
polyubiquitinated species of APPL1 upon overnight treatment
with MG132 (Fig. 5B). Again, in the APPL1 immunoprecipitates
there were multiple bands recognized both by anti-APPL1 and
anti-ubiquitin antibodies, as well as a ubiquitin-immunoreactive
smear of high molecular weight (Fig. 5B). Thus, endogenous
APPL1 is ubiquitinated in HeLa cells under proteasomal stress
conditions.
K63-linked polyubiquitination has been reported to promote
sequestration of misfolded proteins into aggresomes and their
subsequent clearance by autophagy [36]. We wished to deter-
mine if the ubiquitin chains conjugated to APPL1 are linked by
K63. Thus we overexpressed APPL1 in HEK293 cells together with
the wild type HA-tagged ubiquitin or one of the two mutants:
with all lysines but K63 mutated to arginine (K63-only), or with
K63 single lysine-to-arginine replacement (K63R). The extent of
modifications of overall cellular proteins by both ubiquitin
mutants was lower than in the case of wild type ubiquitin,
which was visible in the lysates probed with anti-HA antibody
(Fig. 5C). An anti-HA-reactive band above the size of APPL1
appeared in immunoprecipitates of APPL1 from cells expressing
wild type and K63-only ubiquitin (Fig. 5C). In addition, an HA-
immunoreactive smear of high molecular weight was formed in
the APPL1 immunoprecipitates by the wild type and K63-only
ubiquitin, but not by the K63R mutant (Fig. 5C). This result
indicates that the ubiquitin molecules conjugated to APPL1 can
be linked via a K63-mediated bond.
One of E3 ubiquitin ligases participating in the modification of
endocytic targets via K63-linked ubiquitin chains is Nedd4 (neural
precursor cell-expressed developmentally downregulated gene 4)
[37].We overexpressed APPL1 and FLAG-ubiquitin with orwithout
human untagged or mouse HA-tagged Nedd4 in HEK293 cells.
Compared to control cells, we could detect much stronger,
multiple APPL1-immunoreactive bands both in the lysates and
the APPL1 immunoprecipitates from cells transfected with the
Nedd4 ligases (Fig. 5D). In contrast, overexpression of RING-type
E3 ligase c-Cbl did not enhance the amount of ubiquitinated APPL1
despite increasing overall ubiquitination of cellular proteins. This
would suggest that Nedd4 is a specific E3 ubiquitin ligase for
APPL1.Fig. 4 – The role of APPL1 in aggresome formation and clearance. (
with GFP-APPL1; 24 h later they were treated with 10 μΜ MG132 f
endogenous ubiquitin. Insets show a magnification of aggregates o
(B) HeLa cells seeded on coverslips were transfected with 10 nM si
treatedwith 5 μMMG132 for 18 h, fixed and co-stained for ubiquitin
transfected with two independent control siRNAs and two siRNA d
MG132 for 18 h, washed and allowed to grow in normal medium fo
APPL1 and DAPI. Cells containing clusters of ubiquitin were groupe
shown in upper panel; scale bar 20 μm). The cells were counted and
n=566 for control siRNAs and n=713 for APPL1 siRNAs). The graph
sequences with standard deviation. *, p<0.05; ns, not significant co
show the efficiency of APPL1 knockdown in comparison to α-tubuli
siRNA duplexes. The cells used for Western blot were grown and tre
they were either lysed or fixed at the same time.Solubility of APPL1
As aggresomes contain high amounts of detergent-insoluble
proteins [19], we hypothesized that the localization of APPL1 to
these structures could result from its enhanced insolubility. To
assess if the treatment with MG132 alters the solubility of APPL1,
we examined the total, soluble and insoluble fractions of HeLa cells
treated with DMSO or MG132 from 1 to 20 h. Upon protein
extraction with RIPA buffer, APPL1 was almost completely soluble
in untreated and DMSO-treated cells. Its solubility was decreased
with the increasing time of MG132 treatment (Fig. 6A, APPL1 short
exposure). Accordingly, we saw a corresponding increase of APPL1
levels in the detergent-insoluble fraction. Upon 20-h treatment
with MG132, additional APPL1-immunoreactive bands were
detected, in particular in the insoluble cell fraction (Fig. 6A,
APPL1 long exposure). As controls we probed for EEA1 (an
endosomal protein which remains soluble after detergent extrac-
tion), HDAC2 (a nuclear, chromatin-bound and predominantly
insoluble protein) and α-tubulin. While the solubility of EEA1 was
not altered, HDAC2 and α-tubulin displayed a slight decrease in
solubility upon MG132 treatment (Fig. 6A). With respect to the
total protein levels, 20 h of MG132 treatment induced decrease in
APPL1 and EEA1, but not the other tested proteins (Fig. 6A). This
data suggested that APPL1 becomes insoluble under the same
conditions that evoke APPL1 clustering.
In order to check whether ubiquitin conjugates could
correspond to the observed additional bands of APPL1 appear-
ing in an insoluble fraction of HeLa upon prolonged MG132
treatment (Fig. 6A), we performed a similar experiment in
HEK293 cells transiently transfected with APPL1 and HA-
ubiquitin. We blotted the soluble and insoluble fractions for
HA, APPL1 and EEA1, and performed an immunoisolation of
APPL1 from the soluble fraction (Fig. 6B). While MG132 only
moderately increased the overall level of the soluble ubiquiti-
nated proteins upon 20-h treatment, much more ubiquitinated
proteins accumulated in an insoluble cell fraction upon 20-h
treatment by MG132 or ALLN (Fig. 6B). In agreement with the
data from HeLa cells, both these treatments led to enhanced
insolubility of APPL1 and the appearance of multiple APPL1
bands in an insoluble fraction of HEK293 cells (Fig. 6B). In
addition, the prolonged MG132 or ALLN treatment caused an
increase in the levels of ubiquitinated species present in APPL1
immunoprecipitates (Fig. 6B). Similar results were obtainedA) HeLa cells seeded on coverslips were transiently transfected
or additional 6 or 20 h, then fixed and stained for GFP and
f APPL1 from cells treated with MG132 for 20 h. Bar, 20 μm.
RNA (either control or targeting APPL1). After 24 h cells were
and APPL1. Bar, 20 μm. (C) HeLa cells seeded on coverslips were
uplexes against APPL1. After 24 h cells were treated with 5 μM
r additional 24 h. Cells were fixed and co-stained for ubiquitin,
d into four types based on their size (representative images are
expressed as a percentage of scored cells (total number of cells
shows averaged results obtained from two independent siRNA
mpared with control siRNA (Mann–Whitney test). Right panels
n and β-actin levels in cells treatedwith control (ctrl) and APPL1
ated in parallel to the cells used for microscopical analysis and
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increased ubiquitination and insolubility of APPL1 (Fig. S5).
Thus, proteasomal stress induces ubiquitination of APPL1 and
the formation of clusters of ubiquitinated insoluble APPL1.
Changes in APPL1 distribution and solubility depend on
protein synthesis
Efficient protein biosynthesis is prerequisite for the formation of
aggresomes stimulated by bortezomib [38]. We checked how theinhibition of translation with cycloheximide affects the changes in
APPL1 distribution and insolubility, and in particular the formation of
clusters. In addition toMG132,we incubatedHeLa cellswith 10 μg/ml
cycloheximide to block protein synthesis. We observed a complete
loss of clusters in the cells co-treatedwithMG132 and cycloheximide
for 20 h, in comparison to over 50% of cells containing clusters under
MG132-only condition (Fig. 7A). As expected, co-staining of APPL1
and vimentin showed lack of aggresomes in the cells co-treated with
MG132 and cycloheximide for 20 h, like in control cells and in clear
contrast to the cells treated with MG132 alone (Fig. 7B).
Fig. 5 – Ubiquitination of APPL1. (A) Ectopically expressed APPL1 is ubiquitinated in HEK293 cells. Cells were transiently transfected
with untagged APPL1 and HA-ubiquitin (HA-Ub) as indicated, and 48 h later lysed in RIPA buffer. APPL1 and tagged ubiquitin were
detected by Western blotting in the immunoprecipitates (IP) of APPL1 and control rabbit immunoglobulins (Ig). The arrowheads
indicate the positions of ubiquitinated APPL1 species. Both short and long exposures of the blots are shown. (B) Ubiquitination of
endogenous APPL1 in HeLa cells is enhanced by MG132. HeLa cells were treated with DMSO or 5 μMMG132 overnight and lysed in
RIPA supplemented with 10 mM NEM. The resulting lysates were subjected to immunoprecipitation using anti-APPL1 antibodies.
APPL1 and ubiquitin were detected byWestern blotting. (C) APPL1 is modified with K63-linked ubiquitin chains. HEK293 cells were
transiently transfectedwith the untagged APPL1 and the indicatedHA-ubiquitin (Ha-Ub) constructs. After 48 h the cellswere treated
with 5 μMMG132 for 1 h prior to lysis in RIPA buffer. Lysates and immunoprecipitates with anti-APPL1 antibodies were blotted for
HA andAPPL1. Asterisks indicate a position of unmodified APPL1. (D)Ubiquitination of APPL1 is enhanced byNedd4ubiquitin ligase.
HEK293 cells were transiently transfected with the indicated constructs, and 48 h later lysed in RIPA buffer. Lysates and APPL1
immunoprecipitates were resolved by SDS-PAGE and blotted as indicated. Asterisks indicate a position of HA-tagged mouse Nedd4.
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lation of proteasomally degraded proteins, we checked for total
levels of APPL1 in cells treated with MG132 with or without
cycloheximide. HeLa cells treated for 20 h with DMSO or MG132
were incubated for the last 3 h or for the whole 20 h withcycloheximide. The normalized amounts of lysates were blotted for
APPL1, Nedd4, EEA1, and control proteins: HDAC2 and α-tubulin
(Fig. 7C). Cycloheximide decreased the APPL1 level after 3 and 20
h (compare lanes 1, 3, and 5, Fig. 7C). In agreement with data from
Fig. 6A, 20 h of MG132 treatment decreased the amount of APPL1
Fig. 6 – Solubility of APPL1. (A) Prolonged administration of MG132 increases insolubility of APPL1. HeLa cells were treated with
DMSO or 10 μMMG132 for the indicated times. Cells were either lysed in hot sample buffer (for total cell lysates) or in RIPA buffer, in
which case the detergent-soluble and -insoluble fractions were collected. Equal amounts of protein were resolved by SDS-PAGE and
blotted for APPL1 (upper and lower panels depict long and short exposure times, respectively), EEA1, HDAC2 and α-tubulin.
(B) HEK293 cells transfected with APPL1 and HA-ubiquitin (HA-Ub) were treated as indicated, lysed in RIPA buffer and extracted
into the detergent-soluble and -insoluble fractions which were blotted for EEA1, APPL1 and HA. Immunoprecipitates of APPL1 and
control rabbit immunoglobulins (Ig) from the soluble cell fraction were blotted for APPL1 and HA. Asterisks indicate a position of
unmodified APPL1.
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cycloheximide resulted in stabilization of the total APPL1 level
(compare lanes 5–6with 1–2, Fig. 7C). In parallel, blocking of proteinsynthesis decreased the levels of Nedd4 and EEA1. In fact, the levels
of EEA1 were affected by cycloheximide and MG132 treatment in a
manner similar to that described for APPL1 (Fig. 7C). On the other
Fig. 7 – Clustering of APPL1 uponMG132 administration depends on protein synthesis. (A) Quantification of the perinuclear clusters
of APPL1. HeLa cells were seeded on coverslips and treated with 5 μM MG132 for 20 h with or without 10 μg/ml cycloheximide
(CHX). Six random images taken with a maximally opened confocal pinhole were analyzed for each condition; the cells containing
clustered APPL1 were counted and expressed as a percentage of all scored cells (n indicates the number of scored cells). The graph
shows an average of two independent experiments with standard deviation. ***, p<0.001 compared with control MG132 alone
(Mann–Whitney test). (B) HeLa cells were treated for 20 h with control DMSO, 10 μg/ml cycloheximide, 10 μMMG132 alone or both
together. The cells were fixed and stained for APPL1, vimentin and DAPI (blue). Bar, 20 μm. (C) HeLa cells were treatedwith DMSO or
10 μM MG132 with or without 10 μg/ml cycloheximide for the indicated times prior to lysis in hot sample buffer. Equal protein
amounts were resolved on SDS-PAGE followed by detection of levels of the indicated proteins by Western blot. The graph shows
quantification of APPL1 total protein levels from Western blot bands, with average values and standard deviation obtained from
two separate experiments. Calculation has been performed using ImageJ software. (D) HeLa cells were treated as indicated, lysed in
RIPA buffer, centrifuged and extracted into the soluble and insoluble fractions that were subjected to Western blotting using
anti-APPL1 antibodies.
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decreased by 20-h treatment with cycloheximide, and not affected
by MG132 co-treatment (Fig. 7C). We also blotted for APPL1 in the
soluble and insoluble HeLa fractions after co-treatmentwithMG132
and cycloheximide. Strikingly, the ladder of APPL1 appearing upon
20-h MG132 treatment was not present in the cells co-treated with
cycloheximide (Fig. 7D). This suggests that the impairment in
protein synthesis results in a coordinated lack of aggresomes and
APPL1 clusters, which is accompanied by a lack of accumulation of
ubiquitinated insoluble APPL1.Discussion
Recent years brought a number of reports that describe the
participation of an adaptor protein APPL1 in processes related to
cellular growth, proliferation and survival, which at the molecular
level are linked with signal transduction, membrane traffic, and
gene transcription [14]. The ubiquitin–proteasome system is
closely related to all the above processes, and its dysfunction is
associated with a number of pathologies. When the proteasome
function is compromised, or upon overexpression of proteins
normally degraded in proteasomes, ubiquitinated, misfolded and
insoluble proteins accumulate and become sequestered into large
perinuclear inclusion bodies called aggresomes [39].
Given the growing importance of APPL endosomes,wewished to
characterize their fate upon proteasomal stress. Strikingly, we
observed a solubilization of APPL1 from endosomal membranes
whichmade further observations of this endosome class impossible,
since APPL1 is its unique marker. Instead, a prolonged treatment
with all tested proteasome inhibitors caused clustering of APPL1
protein in the perinuclear region. Employing the commonly
accepted criteria, we confirmed that endogenous APPL1 is recruited
toaggresomes formeduponproteasomal inhibition. This discovery is
particularly significant as there are only a handful of known
endogenous proteins that become sequestered in aggresomes.
It couldbe expected that the formationof anaggresome interferes
with theproper localization of perinuclear cellular structures, such as
the Golgi complex, mitochondria and lysosomes, which was
confirmed in our observations. However, APPL1 endosomes are
preferentially located at the cell periphery, and proteasome
inhibition seems to affect specifically their marker protein APPL1
but not a marker of the canonical early endosomes EEA1. MG132
markedly decreases APPL1 labeling of endosomes, while the total
amount of APPL1 protein in the cell is only slightly changed. The
perinuclear APPL1 clusters form in about 50% of cells treated with
MG132 for 20 h, and they meet the criteria describing aggresome
formation: (a) the perinuclear clusters of APPL1 are surrounded by a
cage of vimentin (Fig. 3A); (b) the APPL1 and ubiquitin clusters co-
localize in the same focal plane of an optical section (Fig. 3B);
(c) clusteringof APPL1 is inhibited by amicrotubule-disrupting agent
nocodazole, which also prevents aggresome assembly [19] (Fig. 3C);
(d)uponMG132 treatmentAPPL1 is ubiquitinated (Fig. 5B); (e)upon
proteasome inhibition APPL1 accumulates in a detergent-insoluble
fraction (Fig. 6); (f) clustering andubiquitination ofAPPL1dependon
protein synthesis (Fig. 7). Based on this evidence, we conclude that
proteasomal inhibition induces recruitment of ubiquitinated and
aggregated APPL1 to aggresomes. In HEK293 cells overexpressing
ubiquitin, APPL1 becomes polyubiquitinated with a contribution of
K63-linked ubiquitin chains and the ubiquitin ligase Nedd4 canenhance such polyubiquitination reaction (Fig. 5). This is particularly
interesting in the view of recent reports showing that the non-
degradative K63-linked polyubiquitination promotes sequestration
of proteins into aggresomes [36,40].
There could be at least three explanations for the observed
recruitment of APPL1 to aggresomes induced by the proteasomal
stress. Firstly, if APPL1 was normally a target for proteasomal
degradation, the blockage of proteasomes might have caused an
excessive accumulation and aggregation of APPL1. Since we do not
observe an increase in the total APPL1 protein level upon MG132
treatment, this simple explanation is unlikely. Secondly, protea-
somal stress could cause damage to APPL1 which stays misfolded
and aggregated due to the sequestration of cellular chaperones
that could otherwise help to refold it. Thirdly, APPL1 might co-
assembly with other aggregation-prone proteins. Since APPL1 co-
localizes with aggregates formed by overexpressed GFP-Eps15
upon MG132 treatment (Fig. 3D), one such candidate could be
ubiquilin, which has both ubiquitin-binding and ubiquitin-like
domains, that binds to Eps15 and recruits it to aggresomes [34,35].
It is currently believed that aggresomes represent a protective
cellular response to stress conditions. Importantly, the ubiquitin–
proteasome system and protein aggregation are implicated in the
pathogenesis of several genetic and neurodegenerative disorders
[41]. The proteasome inhibitor bortezomib used in our study is
approved for treatment of patients with relapsed and refractory
multiple myeloma, and its antineoplastic activity has been reported
in a variety of solid andhematological cancers [42]. Anewgeneration
of proteasome inhibitors with improved pharmacological properties
are being developed and await testing for their efficiency in
treatment of other types of malignancies and immune-mediated
disorders [43,44]. Our studies suggest that in clinical practice such
proteasome inhibitors may have some impact on endocytic adaptor
proteins, as they can affect the localization, ubiquitination and
solubility of APPL1. An identification of the signaling pathways that
promote aggresome formation and clearance could be vital for
elucidating the pathophysiology of many diseases associated with
protein misfolding. It would be interesting to check if APPL1 co-
localizeswith aggresomes formedunder disease-relevant conditions
other than proteasomal inhibition, such as overexpression of
huntingtin with polyglutamine expansion or the deletion mutant
of the cystic fibrosis transmembrane regulator (CFTR).
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